ArticleDiscover oncology2025
Early-stage small cell carcinoma of the ovary hypercalcemic type: autologous stem cell transplantation as standard primary treatment.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Small cell carcinoma of the ovary, hypercalcemic type complicated by enterocutaneous fistula: a case report.Journal of medical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) represents less than 0.01% of all ovarian malignancies which affects mostly young women. Most cases are caused by a pathogenic variant (PV) in SMARCA4 gene. Prognosis correlates directly with FIGO stage and multi-modal treatment including optimal cytoreductive surgery plus multi-agent platinum-based chemotherapy is recommended. A case of a 20-year-old female diagnosed with SCCOHT is presented. After surgery, she underwent six cycles of a platinum-based chemotherapy regimen consolidated with an autologous stem cell transplant. She was the first patient diagnosed with SCCOHT to receive a bone marrow transplant in Portugal and, 28 months after the initial diagnosis, has no evidence of relapse. The authors discuss the management of this clinical case in parallel with an updated literature review, and the most recent International SCCOHT Consortium (ISC) guidelines, with emphasis on the role of autologous stem cell transplantation in the early stages of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.